GENMAB A/S (GMAB) Form 6-K — Oct 7, 2026
Genmab A/S held an Extraordinary General Meeting on October 7, 2026, where shareholders approved the Board of Directors' 2026 remuneration proposal, including share-based compensation in the form of restricted stock units. As a result, 5,300 restricted stock units were granted to board members under Genmab's Remuneration Policy. Each RSU is awarded cost-free, valued at DKK 2,487.00 (the closing share price on the grant date), and vests on the first banking day of the month following three years from grant.
Key figures
- Rsus granted
- 5300
- Par value dkk
- 1
- Vesting period
- 3 years from date of grant
- Rsu fair value dkk
- 2,487.00 per unit
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.